| Fund ID | 805-1135587442 |
| Fund type | Hedge Fund |
| 3(c)(1) exclusion | Yes |
| 3(c)(7) exclusion | Yes |
| Master fund | No |
| Feeder fund | No |
| Fund of funds | No |
| Relies on exemption from registration | Yes |
| Annual audit | Yes |
| Prepared per GAAP | Yes |
| Sub-advised | No |
| Sales limited to qualified investors | Yes |
| % of assets independently valued | 100% |
| Owned by the adviser or related persons | 42% |
| Owned by funds of funds | 15% |
| Owned by non-U.S. persons | 2% |
| Fund | Type | Gross assets |
|---|---|---|
| Oncology Impact Fund 2, L.P. | Other Private | $1.01B |
| UBS Oncology Impact Fund L.P. | Other Private | $629.7M |
| Mpm Bioventures 2018, L.P. | Venture Capital | $548.7M |
Bioimpact Equities Fund, LP reports $158.4 million in gross assets, among the top 34% of private funds by size.
The stated minimum investment is $1 million.
Bioimpact Equities Fund, LP is managed by Mpm Asset Management LLC.
No. Private funds are not required to publicly disclose performance. Form ADV reports assets, structure, and service providers.